![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Galectin-1, a member of a family of highly conserved glycan-binding proteins, has emerged as a regulator of immune cell tolerance and homeostasis. This endogenous lectin widely expressed at sites of inflammation and tumour growth, has been postulated as an attractive immunosuppressive agent to restore immune cell tolerance and homeostasis in autoimmune and inflammatory settings. On the other hand, galectin-1 contributes to different steps of tumour progression including cell adhesion, migration and tumour-immune escape, suggesting that blockade of galectin-1 might result in therapeutic benefits in cancer. Recent findings implicating galectin-glycoprotein lattices as selective regulators of inflammatory responses have provided new insights into the understanding of the molecular bases of galectin-1-induced immunoregulation. Here the authors review the dual role of galectin-1 as a selective immunosuppressive agent in T helper (TH)1 and TH17-mediated inflammatory/autoimmune disorders and a potential therapeutic target in cancer and metastasis.
Acknowledgements
The authors apologise to the many authors whose excellent papers could not be cited in this review for space limitations. Work in GA Rabinovich's laboratory is supported by The Cancer Research Institute ‘Elaine R Shepard Memorial Investigator Award’, National Agency for Promotion of Science and Technology (PICT 2003-05-13787), University of Buenos Aires (M091), and a Programme of Fundación Sales/CONICET. GA Rabinovich is a fellow of the John Simon Guggenheim Memorial Foundation New York. M Salatino and GA Rabinovich are members of the research career of CONICET. MA Toscano, JM Ilarregui and GA Bianco thank CONICET and DO Croci thanks the University of Buenos Aires for fellowships granted.